Myeloperoxidase News and Research RSS Feed - Myeloperoxidase News and Research

Myeloperoxidase (MPO) is a peroxidase enzyme most abundantly present in neutrophil granulocytes (a subtype of white blood cells). It is a lysosomal protein stored in azurophilic granules of the neutrophil. MPO has a heme pigment, which causes its green color in secretions rich in neutrophils, such as pus and some forms of mucus.
Boston Heart Diagnostics announces commercial launch of FDA-cleared MPO test

Boston Heart Diagnostics announces commercial launch of FDA-cleared MPO test

Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics into personalized nutrition and lifestyle programs for patients with or at risk for heart disease, announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke. [More]
Good mood reduces stress-induced effects in musicians

Good mood reduces stress-induced effects in musicians

Even professional orchestra musicians suffer from particular stress on the day of the concert and release more cortisol. [More]
Airway alterations present even in young smokers without COPD

Airway alterations present even in young smokers without COPD

A study has found functional and inflammatory changes in the nasal and lower airways of young, healthy smokers in the absence of pulmonary function decline. [More]

New procedure to treat acid reflux can prevent chronic rejection in lung transplant patients

A Loyola University Medical Center study suggests that a procedure to treat acid reflux could help prevent chronic rejection in lung transplant patients. [More]
Research report helps explain how macrophages accumulate triglycerides

Research report helps explain how macrophages accumulate triglycerides

A research report appearing in the Journal of Leukocyte Biology helps explain how specific immune cells, called macrophages, accumulate triglycerides to support their function. [More]

Research identifies new pathway to target with anti-inflammatory drugs

Scientists' discovery of an important step in the body's process for healing wounds may lead to a new way of treating inflammation. [More]

ANCA-associated vasculitis not a single clinical entity

Study findings show distinct subtypes of antineutrophil cytoplasmic antibody-associated vasculitis, distinguished by the target of autoantigen reactivity. [More]

CHL completes $18.4-million Series B financing round

Cleveland HeartLab Inc. (CHL), a leading specialty clinical laboratory and disease management company, today announced the completion of an $18.4-million Series B financing round. [More]

Highly favorable final results from ERGOFLEX initial clinical study for joint pain relief

OXIS International, today announced highly favorable final results from an initial clinical study to assess the beneficial effects of its patent-pending ERGOFLEX joint health formula, launched commercially in December 2010. [More]

OXIS International files patent application to strengthen Ergothioneine intellectual property portfolio

OXIS International, Inc., today announced that is has filed a patent application titled "Methods and Compositions Using Ergothioneine to Treat a Variety of Health Related Factors" with the U.S. Patent and Trademark Office (USPTO). [More]

OXIS introduces ErgoFlex for relief of joint pain

OXIS International, Inc. announces the market launch of ErgoFlex™, a unique new dietary supplement for the relief of joint pain. It is the first in a series of commercial products planned by OXIS. ErgoFlex is the only joint health complex containing the powerful antioxidant Ergothioneine (ERGO), and is specifically formulated to help the body fight the pain of joint inflammation and maintain optimal joint health. [More]
Ergothioneine international congress 2011 to be held at UCLA

Ergothioneine international congress 2011 to be held at UCLA

OXIS International, Inc., today announced that the "First International Congress on Ergothioneine, Anti-Oxidants, and Age Management Medicine" will be held Friday to Sunday, July 15-17, 2011, in the DeNeve Auditorium at the University of California, Los Angeles. [More]
Study reveals two enzymes help immune cells deploy pathogen-killing traps

Study reveals two enzymes help immune cells deploy pathogen-killing traps

A new study reveals that two enzymes help immune cells deploy pathogen-killing traps by unraveling and using the chromatin (DNA and its associated proteins) contained in the cells' nuclei to form defensive webs. The study appears online on October 25 in The Journal of Cell Biology. [More]
Estee Lauder subsidiary and OXIS resolve mitochondria patent dispute

Estee Lauder subsidiary and OXIS resolve mitochondria patent dispute

OXIS INTERNATIONAL, INC. and THE ESTEE LAUDER COMPANIES INC. announce today that they have resolved a dispute between an Estee Lauder subsidiary, Applied Genetics Incorporated Dermatics, and Oxis over technology related to U.S. Patent No. 6,103,746 and U.S. Patent No. 6,479,533, entitled "Methods and Compositions for the Protection of Mitochondria." [More]
First World Congress on Ergothioneine to be held in Los Angeles, California in July 2011

First World Congress on Ergothioneine to be held in Los Angeles, California in July 2011

OXIS INTERNATIONAL, INC. is proud to announce that it has initiated active planning for the First World Congress on Ergothioneine, to be held in Los Angeles, California in July 2011 (the specific date will be announced at a later date). [More]

OXIS International to introduce new ergothioneine-based products for joint health and healthy aging

OXIS INTERNATIONAL, INC. is proud to announce that it will introduce the benefits of Ergothioneine to the consumer market in September 2010 via breakthrough products for joint health and healthy aging. The first products, ErgoFlex® and ErgoPlex®, will initially be marketed via a direct mail offering being developed in partnership with Creative Direct Marketing Group, the leading service provider in the direct mail sector of the direct to consumer channel. [More]
New data on Surfaxin LS presented at 2010 PAS Annual Meeting

New data on Surfaxin LS presented at 2010 PAS Annual Meeting

Discovery Laboratories, Inc., announced that new data regarding Surfaxin LS (its novel, lyophilized KL4 surfactant dosage form) were presented at the 2010 Pediatric Academic Societies Annual Meeting. The two studies presented demonstrate that Surfaxin LS improves lung function and oxygenation while attenuating lung inflammation in the preterm lamb model of respiratory distress syndrome. [More]
Study: Carbon nanotubes degraded by MPO enzyme induce less inflammation

Study: Carbon nanotubes degraded by MPO enzyme induce less inflammation

A team of Swedish and American scientists has shown for the first time that carbon nanotubes can be broken down by an enzyme - myeloperoxidase (MPO) - found in white blood cells. [More]
Scientists show carbon nanotubes can be broken down by MPO

Scientists show carbon nanotubes can be broken down by MPO

A team of Swedish and American scientists has shown for the first time that carbon nanotubes can be broken down by an enzyme - myeloperoxidase - found in white blood cells. Their discoveries are presented in Nature Nanotechnology and contradict what was previously believed, that carbon nanotubes are not broken down in the body or in nature. [More]

Mortality in CAD patients: Key predictor identified

Coronary Artery Disease (CAD) hospitalizes more than 160,000 Canadians every year, and almost one quarter of those patients die from this common form of heart disease. But now a team of Vancouver-based researchers has identified a key predictor of mortality in CAD patients, which means that specialists can better determine how to treat and improve outcomes for patients with CAD. [More]